Phaseline

Companies › Johnson & Johnson (Janssen)

Johnson & Johnson (Janssen): clinical trials, targets and expected readouts

66 active drug programs in 569 registered trials: 270 Phase 2, 149 Phase 1, 110 Phase 3, 40 Phase 4; Oncology, Immunology, Neurology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Guselkumab (CNTO1959)
Interleukin-23 inhibitor
IL12B, IL23APhase 4Arthritis, Psoriatic; Psoriasis; Colitis, Ulcerative; Crohn's Disease …Dec 2026
Ciltacabtagene Autoleucel (JNJ-68284528)
Tumor necrosis factor receptor superfamily member 17 binding agent
TNFRSF17Phase 4Multiple Myeloma; Recurrent Multiple Myeloma; High Risk Smoldering Multiple Myeloma; Relapse Multiple Myeloma …Feb 2027
Daratumumab
Lymphocyte differentiation antigen CD38 inhibitor
CD38Phase 3Multiple Myeloma; Amyloidosis; Hemophilia A With Inhibitor; Microvascular Inflammation - MVI in Kindey Transplant Recipients …Nov 2026
Apalutamide
Androgen Receptor antagonist
ARPhase 3Prostatic Neoplasms; Metastatic Castrate-sensitive Prostate CancerDec 2026
Milvexian
Coagulation factor XI inhibitor
F11Phase 3Ischemic Stroke; Ischemic Attack, Transient; Atrial FibrillationDec 2026
Nipocalimab
IgG receptor FcRn large subunit p51 antagonist
FCGRTPhase 3Hemolytic Disease of the Fetus and Newborn; Myasthenia Gravis; Thrombocytopenia, Neonatal Alloimmune; Sjogrens Syndrome …Dec 2026
Cetrelimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Urinary Bladder Neoplasms; Bladder Cancer; Prostatic Neoplasms, Castration-Resistant; Neoplasms …Dec 2026
Seltorexant
Orexin receptor 2 antagonist
HCRTR2Phase 3Depressive Disorder, MajorDec 2026
Amivantamab
Epidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhibitor
EGFR, METPhase 3Advanced or Metastatic Non-small Cell Lung Cancer; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck …Dec 2026
Erdafitinib (TAR-210)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 3Urothelial Cancer; Non-Muscle Invasive Bladder Neoplasms; Urothelial Carcinoma; Advanced Malignant Solid Neoplasm …Dec 2026
Ibrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Anemia; Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type …Dec 2026
Lazertinib
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Advanced or Metastatic Non-small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Non-small-Cell Lung; Non-Small-Cell Lung Cancer …Dec 2026
Niraparib
Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor
PARP2, PARP1Phase 3Prostatic Neoplasms; Castration-Resistant Prostatic Cancer; Prostatic Neoplasms, Castration-Resistant; Ovarian Cancer …Dec 2026
selexipag
Prostanoid IP receptor agonist
PTGIRPhase 3Hypertension, Pulmonary; Pulmonary Arterial HypertensionDec 2026
Pasritamig
FGFR3 inhibitor
FGFR3Phase 3Prostatic Neoplasms, Castration-Resistant; Metastatic Castration-resistant Prostatic Neoplasms; Prostatic Neoplasms; Metastatic Castration-resistant Prostate NeoplasmsJan 2027
Macitentan
Endothelin receptor, ET-A/ET-B antagonist
EDNRB, EDNRAPhase 3Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Combined Pre- and Post-capillary Pulmonary HypertensionJan 2027
Golimumab
TNF-alpha inhibitor
TNFPhase 3Colitis, Ulcerative; Rheumatoid Arthritis; Peripheral SpondyloarthritisFeb 2027
Icotrokinra (JNJ-77242113)
IL-6 receptor antagonist
IL6RPhase 3Arthritis, Psoriatic; Plaque Psoriasis; Colitis, Ulcerative; Crohn DiseaseFeb 2027
Talquetamab
T cell surface glycoprotein CD3 binding agent; G-protein coupled receptor family C group 5 member D binding agent
CD3E, CD3G, CD3D, GPRC5DPhase 3Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) …Apr 2027
Teclistamab
T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent
CD3E, CD3G, CD3D, TNFRSF17Phase 3Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) …Apr 2027
JNJ-79635322
Bispecific antibody targeting CD3 and BCMA
CD3E, TNFRSF17Phase 3Multiple Myeloma; Relapsed or Refractory Multiple MyelomaApr 2027
HLD-0915 (JNJ-101556143)
HLD-0915; mechanism unclear from registry
–Phase 3Prostatic Neoplasms; Metastatic Prostate CancerJun 2027
JNJ-87189401
PSMA-targeted CD28 co-stimulatory agonist bispecific antibody
FOLH1Phase 3Metastatic Castration-resistant Prostatic Neoplasms; Prostatic NeoplasmsJun 2027
Bleximenib
Menin inhibitor
MEN1Phase 3Leukemia, Myeloid, Acute; Acute Leukemia; Acute Myeloid LeukemiaJun 2027
Ustekinumab
Interleukin-12 inhibitor; Interleukin-23 inhibitor
IL12B, IL12A, IL23APhase 3Crohn Disease; Psoriasis; Crohn Disease (CD); Type 1 Diabetes Mellitus …Sep 2027
JNJ-77242113
TYK2 inhibitor
–Phase 3Generalized Pustular PsoriasisOct 2027
Abiraterone acetate
Cytochrome P450 17A1 inhibitor
CYP17A1Phase 3Prostatic Neoplasms; Prostate Cancer; Castration-Resistant Prostatic Cancer; Metastatic Prostate Cancer …Nov 2027
Ramantamig
BCMAxGPRC5DxCD3 trispecific antibody
TNFRSF17, CD3E, BCMA, GPRC5DPhase 3Multiple MyelomaDec 2027
JNJ-78934804
IL-23 inhibitor
IL23APhase 3Crohn Disease; Colitis, Ulcerative; Crohn's DiseaseJun 2028
JNJ-90301900 (NBTXR3)
Hafnium oxide nanoparticles that generate oxygen free radicals when activated by ionizing
–Phase 3Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and NeckJun 2028
Esketamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Depressive Disorder, Treatment-Resistant; Depressive Disorder, Major; Sleep Wake Disorders; Prenatal Depression …Dec 2028
JNJ-95597528–Phase 2Dermatitis, Atopic; AsthmaNov 2026
JNJ-64042056
Anti-tau monoclonal antibody
–Phase 2Alzheimer DiseaseDec 2026
JNJ-88545223–Phase 2Arthritis, PsoriaticJun 2027
JNJ-81201887
AAV5-delivered CD59 complement regulator
CD59Phase 2Geographic AtrophyAug 2029
JNJ-69086420
Actinium-225-labeled anti-hK2 antibody (alpha-particle emitting radiopharmaceutical)
KLK2Phase 1Prostatic NeoplasmsDec 2026
JNJ-78278343
KLK2-CD3 bispecific antibody (pasritamig)
KLK2, CD3EPhase 1Prostatic NeoplasmsDec 2026
JNJ-89862175–Phase 1Advanced-stage Solid TumorsDec 2026
ARX517
anti-PSMA antibody-drug conjugate with microtubule-disrupting toxins
FOLH1Phase 1Metastatic Prostate CancerDec 2026
JNJ-90009530
autologous chimeric antigen receptor (CAR)-T cell therapy targeting CD20
–Phase 1Relapsed or Refractory B Cell Non-Hodgkin LymphomaJan 2027
JNJ-86974680
ARv7 inhibitor
ARPhase 1Prostatic NeoplasmsJan 2027
JNJ-87890387–Phase 1NeoplasmsMar 2027
JNJ-75348780
CD3 T-cell engager
–Phase 1Lymphoma, Non-HodgkinMar 2027
JNJ-80948543
T-cell redirecting trispecific antibody against CD79b, CD20, and CD3
CD79B, CD20, CD3Phase 1Lymphoma, Non-HodgkinMar 2027
Cetrelimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 1Carcinoma, Non-small-Cell Lung; NeoplasmsApr 2027
JNJ-86974680–Phase 1Carcinoma, Non-small-Cell LungApr 2027
Capmatinib
Hepatocyte growth factor receptor inhibitor
METPhase 1Carcinoma, Non-Small-Cell LungApr 2027
JNJ-88549968
CALR-targeting therapy for calreticulin-mutated myeloproliferative neoplasms
CALRPhase 1NeoplasmsJun 2027
Aticaprant (JNJ-67953964)
Kappa opioid receptor antagonist
OPRK1Phase 1SchizophreniaJun 2027
JNJ-90189892–Phase 1Leukemia, Myeloid, AcuteAug 2027
JNJ-88998377–Phase 1Lymphoma, Non-HodgkinOct 2027
JNJ-87562761–Phase 1Relapsed or Refractory Multiple MyelomaNov 2027
JNJ-95437446–Phase 1Advanced Stage Solid TumorsNov 2027
JNJ-95298177–Phase 1Prostatic NeoplasmsNov 2027
PD-1 Inhibitor
PD-1 inhibitor (specific agent not named)
–Phase 1Relapsed/ Refractory Multiple Myeloma; Esophageal Squamous Cell Carcinoma; Esophageal Carcinoma; Advanced NSCLC …Dec 2027
JNJ-1761981–Phase 1NeoplasmsJan 2028
JNJ-89402638–Phase 1Colorectal NeoplasmsFeb 2028
JNJ-101684362 (HLD-0117)–Phase 1Metastatic Breast CancerApr 2028
JNJ-87801493–Phase 1Lymphoma, Non-HodgkinAug 2028
JNJ-95566692–Phase 1Lymphoma, Non-HodgkinAug 2028
JNJ-87704916
Intratumoral immunotherapy agent
–Phase 1NeoplasmsNov 2028
Olomorasib
KRAS G12C inhibitor
KRASPhase 1Carcinoma, Non-Small-Cell LungNov 2028
JNJ-98768111–Phase 1Prostatic NeoplasmsMar 2029
JNJ-95804306–Phase 1Hematologic NeoplasmsMay 2029
JNJ-90014496
Autologous dual targeting CAR-T cell therapy targeting CD20 and CD19
–Phase 1Lymphoma, Non-HodgkinJul 2041
JNJ-89853413–Phase 1Leukemia, Myeloid, Acute–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01589302IbrutinibPhase 2Prolymphocytic LeukemiaOncologyJul 2016
NCT02048813IbrutinibPhase 3AnemiaOncologyOct 2018
NCT03236428DaratumumabPhase 2Monoclonal GammopathyOncologyOct 2021
NCT04667663DaratumumabPhase 1Multiple MyelomaOncologyApr 2022
NCT03734198DaratumumabPhase 2Relapsed or Refractory Chronic Lymphocytic LeukemiaOncologyJun 2023
NCT03734198IbrutinibPhase 2Relapsed or Refractory Chronic Lymphocytic LeukemiaOncologyJun 2023
NCT04140162DaratumumabPhase 2Multiple MyelomaOncologyMay 2024
NCT05601973AmivantamabPhase 2Non Small Cell Lung CancerOncologyAug 2024
NCT05601973LazertinibPhase 2Non Small Cell Lung CancerOncologyAug 2024
NCT04586426TeclistamabPhase 1Multiple MyelomaOncologyMar 2025
NCT04586426TalquetamabPhase 1Multiple MyelomaOncologyMar 2025
NCT02807805Abiraterone acetatePhase 2Metastatic Prostate CarcinomaOncologyMay 2025
NCT03290950DaratumumabPhase 2Multiple MyelomaOncologyMay 2025
NCT06920576EsketaminePhase 1Chronic RhinosinusitisRespiratoryJul 2025
NCT05379634NipocalimabPhase 2MyositisOtherSep 2025
NCT06778811EsketaminePhase 4Sleep Wake DisordersNeurologySep 2025
NCT05870761NiraparibPhase 2Recurrent Endometrial Serous AdenocarcinomaOncologySep 2025
NCT05698394EsketaminePhase 4Prenatal DepressionPsychiatryOct 2025
NCT06062550EsketaminePhase 4Scoliosis CorrectionGenitourinaryOct 2025
NCT05403138DaratumumabPhase 2Neuromyelitis OpticaNeurologyNov 2025
NCT06853431EsketaminePhase 4Preoperative AnxietyPsychiatryNov 2025
NCT06087510EsketaminePhase 4Scoliosis CorrectionGenitourinaryDec 2025
NCT07001709Abiraterone acetatePhase 4Prostate CancerOncologyDec 2025
NCT04221503NiraparibPhase 2GlioblastomaOncologyJan 2026
NCT06139406JNJ-80948543Phase 1Lymphoma, Non-HodgkinOncologyJan 2026
NCT06139406JNJ-75348780Phase 1Lymphoma, Non-HodgkinOncologyJan 2026
NCT06139406JNJ-87801493Phase 1Lymphoma, Non-HodgkinOncologyJan 2026
NCT03941132UstekinumabPhase 2Type 1 Diabetes MellitusMetabolic and endocrineFeb 2026
NCT06751849PD-1 InhibitorPhase 2Advanced NSCLCOncologyMar 2026
NCT06751901PD-1 InhibitorPhase 2Advanced NSCLCOncologyMar 2026
NCT05450432EsketaminePhase 4Major Depressive DisorderPsychiatryJun 2026
NCT03500445DaratumumabPhase 2MyelomaOncologyJun 2026
NCT06251076TeclistamabPhase 4Multiple MyelomaOncologyJun 2026
NCT07317206EsketaminePhase 2Posttraumatic Stress Disorder (PTSD)PsychiatryJun 2026
NCT07556172EsketaminePhase 4SepsisInfectious diseaseJun 2026
NCT03836014DaratumumabPhase 3Multiple Myeloma in RelapseOncologyJul 2026
NCT07063199DaratumumabPhase 2Immune ThrombocytopeniaHematologyAug 2026
NCT06838962DaratumumabPhase 2Immune ThrombocytopeniaHematologyAug 2026
NCT03589222DaratumumabPhase 2Refractory Multiple MyelomaOncologyAug 2026
NCT07021677DaratumumabPhase 2T Acute Lymphoblastic LeukemiaOncologyAug 2026
NCT06618001JNJ-89853413Phase 1Leukemia, Myeloid, AcuteOncologySep 2026
NCT06083922DaratumumabPhase 2Multiple MyelomaOncologyOct 2026
NCT05702034MilvexianPhase 3Ischemic Stroke; Ischemic Attack, TransientNeurologyOct 2026
NCT03479268IbrutinibPhase 1B-Cell Prolymphocytic LeukemiaOncologyNov 2026
NCT05250973DaratumumabPhase 2AmyloidosisMetabolic and endocrineNov 2026
NCT05117931AmivantamabPhase 2Esophagogastric CancerOncologyNov 2026
NCT03767075AmivantamabPhase 2Advanced Solid TumorOncologyNov 2026
NCT06505369TeclistamabPhase 2Multiple MyelomaOncologyNov 2026
NCT05526989NiraparibPhase 2Penile CarcinomaOncologyNov 2026
NCT06505369TalquetamabPhase 2Multiple MyelomaOncologyNov 2026
NCT05694312IbrutinibPhase 2Autoimmune Hemolytic AnemiaOncologyNov 2026
NCT06859892EsketaminePhase 4AdultsCardiovascularNov 2026
NCT07230860JNJ-95597528Phase 2Dermatitis, AtopicImmunologyNov 2026
NCT07179913EsketaminePhase 4DepressedPsychiatryNov 2026
NCT05463224LazertinibPhase 2NSCLCOncologyDec 2026
NCT03767244ApalutamidePhase 3Prostatic NeoplasmsOncologyDec 2026
NCT04963153Erdafitinib (TAR-210)Phase 1Locally Advanced Bladder Urothelial CarcinomaOncologyDec 2026
NCT05888870DaratumumabPhase 4Hemophilia A With InhibitorHematologyDec 2026
NCT06758375TeclistamabPhase 2Multiple Myeloma, Newly DiagnosedOncologyDec 2026
NCT04992013NiraparibPhase 2Metastatic CancerOncologyDec 2026

The 60 nearest readouts of 569 trials; the rest in the app.

From the company's SEC filings

Cash and short-term investments of $17.2bn on 2026-09-27; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Targets

CD3E (5) TNFRSF17 (4) IL23A (3) EGFR (2) MET (2) AR (2) FGFR3 (2) GPRC5D (2) CD3G (2) CD3D (2) PDCD1 (2) FOLH1 (2)

Companies with the same targets

AstraZeneca Pfizer Shanghai Henlius Biotech Regeneron Pharmaceuticals AbbVie Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Betta Pharmaceuticals Novartis Amgen

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.